A single-arm feasibility trial of memantine to prevent chemotherapy-related cognitive decline in patients with early breast cancer

MLA

Zev Nakamura, et al. “A Single-Arm Feasibility Trial of Memantine to Prevent Chemotherapy-Related Cognitive Decline in Patients with Early Breast Cancer.” Journal of Clinical Oncology, vol. 40, June 2022, p. 12109. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.12109.

APA

Zev Nakamura, Allison Mary Deal, Eliza Myung Park, Kate Stanton, Yesy Lopez, Laura J. Quillen, Erin O’Hare Kelly, Hillary M Heiling, Kirsten A. Nyrop, Emily Miller Ray, Elizabeth Claire Dees, Katherine Elizabeth Reeder-Hayes, Trevor Augustus Jolly, Lisa A. Carey, Yara Abdou, Oludamilola A. Olajide, Megan Ann McNamara, Tim Ahles, & Hyman B. Muss. (2022). A single-arm feasibility trial of memantine to prevent chemotherapy-related cognitive decline in patients with early breast cancer. Journal of Clinical Oncology, 40, 12109. https://doi.org/10.1200/jco.2022.40.16_suppl.12109

Chicago

Zev Nakamura, Allison Mary Deal, Eliza Myung Park, Kate Stanton, Yesy Lopez, Laura J. Quillen, Erin O’Hare Kelly, et al. 2022. “A Single-Arm Feasibility Trial of Memantine to Prevent Chemotherapy-Related Cognitive Decline in Patients with Early Breast Cancer.” Journal of Clinical Oncology 40 (June): 12109. doi:10.1200/jco.2022.40.16_suppl.12109.